IMNN-001 continues to show a favorable safety profile.

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treatedLAWRENCEVILLE, N.J., Sept (GLOBE ...

Ardena Acquired Catalent’s Somerset, NJ, oral solids development and small-scale drug product manufacturing facility for an undisclosed price, in a deal completed in February. In Somerset, expanded ...

In this GEN webinar, our expert speakers will present a case study demonstrating the exceptional properties and high-fidelity performance of ENFINIA Linear DNA.

The case raised concerns about whether Chinese nationals were part of a campaign to terrorize the U.S. agricultural industry ...

University of Iowa researchers developed a gene therapy that could prevent craniosynostosis, a condition where babies’ skull ...

The webcast will be available for 90 days at the link above or under the News & Investors tab of the Imunon website at IMUNON is a clinical-stage biotechnology company focused on advancing a ...

IMUNON (IMNN) announced that new translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of ...

Bucking the trend of IL-12 therapy program failures, Imunon’s IMNN-001 was bolstered by positive translational data in ovarian cancer.

The authors argue that male-biased expression of Cyp17a2 is implicated in mediating infection levels through STING and USP8 activity regulation. Thus, this study highlights an unexpected factor ...

One of two University of Michigan scholars from China accused of smuggling biological material into the United States was sentenced Wednesday to time served and is expected to ...

LONDON, GREATER LONDON, UNITED KINGDOM, September 11, 2025 /EINPresswire.com/ -- What Is The Expected Cagr For The Gene Therapy On Neurological Diseases Market Through 2025? Rapid expansion has been ...